These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 25993881)

  • 1. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives.
    Festi D; Schiumerini R; Marasco G; Scaioli E; Pasqui F; Colecchia A
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1039-53. PubMed ID: 25993881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
    Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
    Festi D; Schiumerini R; Marzi L; Di Biase AR; Mandolesi D; Montrone L; Scaioli E; Bonato G; Marchesini-Reggiani G; Colecchia A
    Aliment Pharmacol Ther; 2013 Feb; 37(4):392-400. PubMed ID: 23278163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
    Castera L
    Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.
    Castera L
    Liver Int; 2018 Feb; 38 Suppl 1():67-70. PubMed ID: 29427494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and natural history of non-alcoholic fatty liver disease.
    Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
    Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease.
    Shen FF; Lu LG
    J Dig Dis; 2016 Sep; 17(9):565-571. PubMed ID: 27429213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of fibrosis markers.
    Patel K; Shackel NA
    Curr Opin Gastroenterol; 2014 May; 30(3):253-9. PubMed ID: 24671009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive diagnosis of advanced fibrosis and cirrhosis.
    Sharma S; Khalili K; Nguyen GC
    World J Gastroenterol; 2014 Dec; 20(45):16820-30. PubMed ID: 25492996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.
    Fitzpatrick E; Dhawan A
    World J Gastroenterol; 2014 Aug; 20(31):10851-63. PubMed ID: 25152587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.
    Eddowes PJ; McDonald N; Davies N; Semple SIK; Kendall TJ; Hodson J; Newsome PN; Flintham RB; Wesolowski R; Blake L; Duarte RV; Kelly CJ; Herlihy AH; Kelly MD; Olliff SP; Hübscher SG; Fallowfield JA; Hirschfield GM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):631-644. PubMed ID: 29271504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Magnetic Resonance Elastography and Non-Alcoholic Fatty Liver Disease: Time for an Upgrade?
    Flores A; Asrani SK
    Am J Gastroenterol; 2016 Jul; 111(7):995-6. PubMed ID: 27356823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.